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Introduction
Acute Myeloid Leukaemia (AML) is a group of  heterogenous 
hematological malignancies characterized by a clonal 
proliferation of  myeloid precursors with a reduced capacity to 
differentiate into more mature cellular elements. As a result, 
there is an accumulation of  leukemic blasts or immature 
forms in the bone marrow, peripheral blood, and occasionally 
in other tissues, with a variable reduction in the production 
of  normal red blood cells, platelets, and mature granulocyte1. 
It accounts for 80% of  the acute leukemias in adults and 15-
20% of  the acute leukaemias in children2. AML constituted 
4.9% of  all haematological cancers with annual incidence of  
1.2 per million in Ilorin, Nigeria3. Patients may present with 
a broad variety of  symptoms including anaemia, low-grade 
fever and easy bruising. Hepatomegaly or splenomegaly 
occurs in about 30% of  the patients with lymphadenopathy 
being extremely uncommon4,5. A presumptive diagnosis 
of  AML can be made via examination of  the peripheral 
blood smear when there are circulating leukemic blasts, 
but a definitive diagnosis usually requires an adequate bone 
marrow aspiration with immunophenotyping3.
In the French-American-British (FAB) Classification, sub-
type classification of  AML is based on morphology and 
cytochemical staining with immunophenotypic data in some 
instances.Types M0, M1, M2, and M3 are predominantly 
granulocytic and differ in the stage of  maturation. The M4 
class is both granulocytic and monocytic, with at least 20% 
of  cells being monocytic. M5 is predominantly monocytic 
with at least 50% being monocytic. M6 shows primarily 
differentiation with dysplastic features and megaloblastic 
changes. The AML classified as acute megakaryocytic 
leukemia is M7 and is characterized by the presence of  
megakaryocytic antigens demonstrated by flow cytometry, 
immunohistochemistry or the presence of  platelet 
peroxides6-7.
Acute megakaryoblastic leukemia (AMegL) is a rare subtype 
of  AML developing from primitive megakaryoblasts, first 
described by Von Boros et al in 19318 . It accounted for 1.2% 
of  newly diagnosed AML by Eastern Cooperative Oncology 
Group (ECOG) trials between 1984 and 1997 9. The disease 
can be identified by antibodies to glycoprotein Ib (CD42), 
glycoprotein IIb/IIIa (CD41a) and glycoprotein IIIa (CD61), 
and is often associated with extensive myelofibrosis10-11. This 
case of  a 19-year old lady is reported because of  the rarity of  
the disease and the fact that no such case has been reported 
in Nigeria.
Case presentation 
A 19-year old Nigerian female, secondary school leaver, 
presented at Olabisi Onabanjo University Teaching 
Hospital, Sagamu, Nigeria, with recurrent headache, fever, 
easy fatiguability and breathlessness of  2 months duration. 
She was treated at a private hospital for typhoid fever and 
malaria with intravenous medications and fluid. She was also 
transfused with 3 units of  blood for symptomatic anaemia. 
The symptoms, however, started again 3 days prior to 
presentation at our accident and emergency unit.
On examination, she was severely pale with slight tinge of  
jaundice. There was no significant peripheral lymph node 
enlargement or evidence of  bleeding from orifices or from 
the gum. There was no bleeding into the skin or pedal 
oedema. The chest was clinically clear. Liver and spleen were 
not palpable.
A full blood count (FBC) done by an automated haematology 
analyzer showed a packed cell volume (PCV) of  10.8 white 
blood cell (WBC) count of  4.1 X 109 /L (Neutrophil-18.3%, 
lymphocyte -78%, mid-3.4%) and platelet of  50 x 109 
/L. Review of  peripheral blood film showed normocytic 
normochromic red blood cells including few nucleated red 
blood cells and immature mononuclear cells with cytoplasmic 
blebs (Figure 1). 
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Acute Megakaryoblastic Leukaemia (AML, M7) is a rare type of  acute myeloid leukemia (AML) evolving from primitive megakaryoblasts. 
It accounted for 1.2% of  newly diagnosed AML according to Eastern Cooperative Oncology Group (ECOG) trials between 1984 and 
1997. Patients may present with a broad variety of  symptoms including low-grade fever, easy bruising, and life-threatening conditions. 
We report a rare case of  AML, M7 in a 19-year-old lady who presented with weakness and fatigue. She was diagnosed as a case of  AML, 
M7 on the basis of  peripheral blood finding, bone marrow examination report, radiological findings and immunophenotyping.
Key words: acute myeloid leukemia, acute megakaryocytic leukaemia, immunophenotyping, myelosclerosis
Malawi Medical Journal 30 (4); 298-301 December 2018 Case of acute megakaryoblastic leukaemia 299
https://dx.doi.org/10.4314/mmj.v30i4.15
Figure 1: Peripheral blood film showing normocytic 
normochromic red blood cells and immature 
mononuclear cells with cytoplasmic blebs
There were giant forms of  platelets on the film. The bone 
marrow aspiration yielded a dry tap which necessitated a bone 
marrow biopsy. The bone marrow imprint showed increased 
immature mononuclear cells with abundant basophilic 
cytoplasm containing vacuoles and hyperchromatic and 
pleomorphic nuclei. Some of  the immature mononuclear 
cells had cytoplasmic blebs and constituted over 90% of  
nucleated cells (Figure 2). 
Figure 2: The bone marrow imprint showing increased 
immature mononuclear cells with abundant basophilic 
cytoplasm containing vacuoles and hyperchromatic 
and pleomorphic nuclei, some have cytoplasmic blebs
The overall picture was in keeping with AML, most likely 
Acute Megakaryoblastic Leukaemia (AML, M7), which was 
confirmed by immunophenotyping (carried out by Safety 
Molecular Pathology Laboratory, Enugu) of  peripheral 
blood with positivity for CD 33, CD41 and CD 61. CD41 
and CD61 are megakaryocyte specific antigens, and CD33 is 
a myeloid marker. The percentage positivity and micrographs 
are shown in Table 1 and Figures 3 and 4. The biochemical 
parameters such as uric acid, bilirubin, creatinine, liver 
enzymes were normal. X-rays of  tibia and fibula showed 
increased fibrosis (figure 5).
She was admitted and resuscitated with empirical intravenous 
antibiotic, intravenous fluid and a transfusion with 5 
units of  fresh whole blood because the facility for blood 
component therapy was not available to cater for anaemia 
and thrombocytopaenia that the patient had. Therapy was 
initiated thereafter with cytarabine and daunorubicin (7+ 3) 
regimen.
Table 1: Percentage positivity of CD33, CD41, CD




*CD – Cluster of  differentiation
Repeat FBC on the seventh day of  induction showed 
PCV of  17.7%, WBC of  0.38 X 109/L and platelet of  
22 X 109 /L. Peripheral blood film revealed leucopeania, 
thrombocytopaenia and there was no abnormal mononuclear 
cell. She was transfused with 2 more units of  fresh whole 
blood. A repeat bone marrow aspiration was done for 
assessment of  remission. Marrow was aspirated with ease 
and blasts were less than 5%. She was then scheduled for 
consolidation therapy. Her parents requested for discharge 
from the hospital due to financial constraint with the promise 
to return after purchasing the chemotherapeutic drugs. She 
was discharged and is yet to return to care.
Figure 3:  Peripheral blood with positivity for CD 33
Figure 4: Peripheral blood with positivity for CD41
Figure 5: X-rays of tibia and fibula showing increased fibrosis
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Discussion
AML, M7 is a rare subtype of  leukemia accounting to 1.2% 
of  cases of  adult AML, compared to 3-10% of  childhood 
AML12. It is as under M7 in the French-American-British 
classification13. The patient was a 19-year old female with 
clinical features similar to other types of  AML except for 
organomegaly noted infrequently in adults which was the 
case with our patient. In our patient, symptoms of  anemia 
were easy fatiguability and breathlessness. Cytopenias are 
usually present but 30% of  patients have platelet counts 
in excess of  1000 x109/L.10 In our patient, bicytopaenia 
(PCV-10.8%, WBC-4.1x 109/L, platelet count- 50 x109/L) 
was found. Osteosclerosis was found in our patient in 
line with osteosclerotic and osteolytic lesions described in 
few case reports14,15. This might be due to production of  
platelet-derived growth factor (PDGF) and transforming 
growth factor β with their  attendant fibroblastic activity. 
Myelofibrosis has been hypothesized to be a reactive 
phenomenon secondary to myeloid disorders. It has been 
postulated that defective or abnormal megakaryocytes and 
the release of  growth factors such as platelet-derived growth 
factor (PDGF), and transforming growth factors (TGF)-β 
are responsible for the development of  myelofibrosis16. 
PDGF is a major mitogen for connective tissue cells such as 
fibroblasts and smooth muscle cells17,18. TGF-β consists of  a 
family of  proteins and has broad effects on many types of  
cells, including fibroblasts and osteoblasts19.
The diagnosis depends on the expression of  at least one 
platelet antigen (CD41, CD42b, and CD61) on the leukemic 
cells10-11. In our patient, peripheral film showed immature 
mononuclear cells with cytoplasmic blebs. Bone marrow 
aspiration was difficult probably due to intense myelofibrosis 
which has been documented in most patients14-15. Bone 
marrow biopsy imprint examined for cytology was relied 
upon for initial diagnosis.
Non-specific, cytogenetic abnormalities are more frequent 
(>90%) in AML, M7 than in other subtypes of  AML.15,20 
Cytogenetic analysis was not carried out due to non-
availability of  the facility. AML, M7 may present as de 
novo leukemia, secondary leukemia after chemotherapy, 
or transformed myeloproliferative disorders and 
myelodysplastic syndromes.21 Our patient had clinical and 
haematologic remission and remains stable but neutropaenic 
before discharge against medical advice. This is consistent 
with the previously observed remission and long term 
survival in spite of  generally poor prognosis of  AML, M720.
Conclusion
To our knowledge, this is the first case of  AML M7 in 
the literature in our environment. The lesson here is that 
proficiency in morphologic diagnosis remains the window 
through which uncommon diagnosis can be confirmed 
by molecular technology particularly in resource-limited 
settings.
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